Treatment Of Cancer With Human Chorionic Gonadotropin
Description of Invention:
A major complication in treating tumors is that many of the known treatments, such as surgery, radiation or chemotherapy, have serious side effects. Other types of cancers are not amenable to conventional therapies due to the fact that the exact mechanism by which the disease develops is unknown. An example of this type of cancer is Kaposi's sarcoma. Kaposi's sarcoma is the most common malignancy in AIDS patients. Current therapies for Kaposi's sarcoma can cause myelotoxicity and neurotoxicity. In addition, these treatments can also induce immunosuppression. This invention describes the use of a naturally occurring human hormone, human chorionic gonadotropin, for the treatment of Kaposi's sarcoma. Human chorionic gonadotropin may also be useful for the treatment of breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas.
Inventors:
Y Lunardi-Iskandar (NCI) RC Gallo (NCI) JL Bryant (NIDCR)
Patent Status:
DHHS Reference No. E-226-1993/0 --
U.S. Patent 5,677,275 issued 14 Oct 1997
U.S. Patent 5,877,148 issued 02 Mar 1999
Portfolios: Infectious Diseases Cancer
Cancer -Therapeutics-Conventional Chemotherapy-Hormonal Compounds Infectious Diseases -Therapeutics-Anti-Viral-AIDS (only) Cancer -Therapeutics Infectious Diseases -Therapeutics
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
